Formulary Watch |

Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.

Officials with OptumRx predict four new therapies that are expected to an impact on patients and on the market.

Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.

Investigators found patients with COPD taking Anoro Ellipta had low overall on-treatment exacerbation rates, which can reduce medical costs due to increased adherence to therapy.

Investigators find there is strong adherence soon after patients fill prescriptions but less consistent use after initial treatment.

ICER’s updated analysis uses observational, real-world data for three therapies — Takhzyro, Haegarda, and Cinryze.

The therapy, to be launched in October, is delivered quickly to the bloodstream by targeting the upper nasal space.

The CDC and the FDA have updated their recommendations for the 2021-2022 flu season.

The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.

Pharmacists are referring patients elsewhere or are shifting patients who were using the IV form to the subcutaneous injection. The NIH has also recommended using Kevzara as an alternative where there are shortages of Actemra.

The approval follows the FDA’s Oncologic Drugs Advisory Committee voting 5-3 in favor of maintaining the approval despite a confirmatory trial that found Keytruda did not meet the end points of overall survival and progression-free survival.

Florida’s First Choice Neurology has provided Aduhelm to patients through the Biogen access program.

The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.

The combination bamlanivimab and etesevimab can resume use and distribution to treat mild-to-moderate COVID-19 but only in states where variants resistant to the therapy are low.

Bluebook Rx is a new solution that helps employers and plan sponsors better understand and optimize their prescription drug spending.

ICER’s policy recommendations suggest payers establish step therapy with less expensive systemic agents to allow patients and clinicians to choose from multiple options.